



Interim report January 1–March 31, 2026

Weak sales, strongly negatively impacted by currency effects and global uncertainty. In the first quarter, sales decreased by 7.2 per cent in constant currency. Order intake developed well with growth of 13.3 per cent in local currency, which gives us a stronger starting point for the coming periods. Cash flow from operating activities improved by 12.7 per cent, driven by improved working capital.

January–March 2026

- » Net revenue was SEK 357.4 million (424.0), a decrease of 15.7%, of which 7.2% was organic and 8.5% currency effects
- » Orders received was SEK 412.8 million (402.5), an increase of 2.6%, of which 13.3% was organic and -10.7% currency effects
- » EBITA was SEK 45.5 million (75.3), a decrease of 39.6%
- » Operating profit (EBIT) was SEK 39.0 million (69.3)
- » Profit for the period was SEK 8.4 million (25.6) and adjusted profit for the period was SEK 14.1 million (25.7).
- » Basic earnings per share amounted to SEK 0.01 (0.10)
- » Operating cash flow was SEK 41.2 million (36.6), an increase of 12.7%

SEK million	Jan–Mar 2026	Jan–Mar 2025	Rolling 12 months Apr 2025– Mar 2026	Jan–Dec 2025	Change
Net revenue	357.4	424.0	1,539.1	1,605.7	-4.1%
EBITA	45.5	75.3	243.5	273.3	-10.9%
EBITA margin, %	12.7%	17.8%	15.8%	17.0%	-1.2 pp
Operating profit/loss (EBIT)	39.0	69.3	201.7	232.0	-13.1%
Operating margin, %	10.9%	16.3%	13.1%	14.5%	-1.4 pp
Profit/loss before tax (EBT)	19.7	37.6	26.2	44.2	-40.6%
Profit/loss for the period	8.4	25.6	-14.0	3.1	-545.7%
Adjusted profit/loss for the period	14.1	25.7	87.4	99.0	-11.7%
Basic earnings per share, SEK	0.01	0.10	-0.02	0.01	-0.03
Return on equity, %	-	-	-1.3%	0.3%	-1.6 pp
Return on capital employed, %	-	-	11.1%	12.6%	-1.5 pp

CEO's comment

Change of ownership and strong order intake

In the first quarter of 2026, net revenue decreased by 15.7 per cent compared with the previous year, strongly negatively impacted by a stronger Swedish krona. In local currency, net revenue decreased by 7.2 per cent. The difference is due to the fact that more than 80 per cent of the Group's sales are in currencies other than SEK. Adjusted for the exchange rate effect, we are not satisfied with sales for the quarter. We see a market situation with continued wait-and-see investment decisions, especially in parts of the laboratory market. Our operations in the Middle East have been significantly affected as a result of the situation in the region where the possibility of maritime transport has been closed. At the same time, it is positive that order intake developed well during the quarter, with organic growth of 13.3 per cent in local currency, which gives us a stronger starting point for the coming periods.

EBITA amounted to SEK 45.5 million (75.3), corresponding to an EBITA margin of 12.7 per cent (17.8). Earnings were impacted by lower volumes and a changed product mix, mainly in our diabetes business, investment-related laboratory equipment and the previously mentioned situation in the Middle East. In 2025, a larger order was delivered to SAAB. This has not been replaced by equivalent volumes during the quarter, although underlying demand is expected to remain stable in the coming periods. Cash flow from operating activities remained stable at SEK 41.2 million (36.6), reflecting solid cash conversion despite weaker earnings. ADDvise continues to strengthen our market positions and our offering in our companies, with a focus on profitability, customer benefit and long-term competitiveness.

During the quarter, a very significant change in ownership was also carried out as Amplex AB, following its public takeover offer, became the owner of more than 99% of the shares in ADDvise and has initiated a compulsory redemption procedure. In connection with the transaction, ADDvise was delisted from Nasdaq First North Premier Growth Market. With effect from 2026, ADDvise constitutes a business area within the Amplex Group. This marks a new phase in the company's development, with a long-term industrial owner who shares our view of value creation through entrepreneurship, decentralisation and acquisitions.



Our financial position remains stable. The equity ratio at the end of the reporting period was 39.0 per cent (24.1) and the Group fulfilled all covenants in its financing agreements. Going forward, the focus is on gradually strengthening profitability, improving tied-up capital and ensuring a reduced level of debt, while continuing to evaluate selective acquisitions that can strengthen the Group's market position and earnings development over time.

In summary, we are not satisfied with the quarter's earnings, but we are confident in our strategy, our business model and our long-term direction. With committed employees, strong niche companies and a clear owner behind it, ADDvise is well positioned to improve, extend and save people's lives.

Staffan Torstensson
CEO

The Group's development

Net revenue and orders

Net revenue for the quarter was SEK 357.4 million (424.0), a decrease of 15.7% year-over-year, of which 7.2% was organic and 8.5% currency effects. Own products and distribution accounted for 56% (55%) and 44% (45%) of the Group's net revenue, respectively.

Orders received for the quarter amounted to SEK 412.8 million (402.5), an increase of 2.6% year-over-year, of which 13.3% was organic and -10.7% currency effects.

Profit

EBITA for the quarter was SEK 45.5 million (75.3), corresponding to a margin of 12.7% (17.8%). During the quarter, non-recurring costs mainly relate to costs incurred during the delisting and compulsory redemption procedure regarding ADDvise's shares and warrants in an amount of SEK 5.2 million, please refer to *Significant events during the reporting period*.

Operating profit for the quarter was SEK 39.0 million (69.3). Profit for the period was SEK 8.4 million (25.6). Basic earnings per share amounted to SEK 0.01 (0.10) for the quarter. Basic earnings per share have been adjusted for the effects of the rights issue and the directed set-off issue completed in April 2025.

During the quarter, adjusted profit for the period was SEK 14.1 million (25.7). For information about acquisition costs and other items in the calculation of the Group's key performance indicators, please refer to Note 10 *Definition of key performance indicators*.

Currency effects

As the Group has subsidiaries outside of Sweden, translation effects occur following changes in the exchange rates for AED, BRL, EUR and USD against the Swedish krona. A strong Swedish krona will mainly affect *Other comprehensive income* in the condensed

consolidated statement of comprehensive income, on the line *Foreign exchange differences on the translation of foreign operations for the period*.

Net financial items

In 2025, the Group's capital structure improved by means of a new bond loan, a new bank facilities agreement and cash from a rights issue, resulting in lower interest expenses. An effect of the refinancing is a negative impact of non-recurring items on net financial items in the second quarter of 2025.

Net financial items during the quarter include a cost of SEK 3.5 million, which is a revaluation of the value of warrants issued by the Group and listed on Nasdaq Stockholm until February 17, 2026. The revaluation is included in net financial items and reported in the *Condensed consolidated statement of comprehensive income* under net financial items, on the line of which is *fair value valuation of derivative financial instruments (warrants)*. See also Note 6 *Calculation of fair value*.

Contingent purchase considerations

Revaluations of contingent purchase considerations had a positive effect on profit for the quarter totaling SEK 4.9 million (25.7), of which SEK 4.9 million (21.7) is reported on the line *Other operating income*. Please refer to Note 6 *Calculation of fair value*.


Tax

The relationship between profit before tax and tax is affected by both non-deductible expenses for tax purposes and non-taxable income.

Return on equity and capital employed

Return on equity was -1.3% (9.1%) for the reporting period. Return on capital employed was 11.1% (12.1%) for the reporting period.

Group net revenue rolling 12 months by quarter by product category



Financial position

Equity and equity ratio

Equity at the end of the reporting period totaled SEK 1,116.6 million (755.6), equating to SEK 1.84 (3.80) per share outstanding. The equity ratio was 39.0% (24.1%). At the end of the reporting period, the company's equity was entirely attributable to the shareholders of the parent company.

Cash and cash equivalents

Cash and bank at the end of the reporting period totaled SEK 70.0 million (276.6). At the end of the reporting period, the Group had a revolving bank credit facility totaling SEK 250.0 million (-), which was utilised in full, and an overdraft facility totaling SEK 50.0 million (-), which was not utilised at the end of the reporting period. At the end of the reporting period, the Group had no short-term investments.

Net debt

Net debt at the end of the reporting period totaled SEK 1,174.8 million (1,454.0). EBITDA rolling 12 months for April 2025–March 2026 was SEK 285.5 million. This gives a ratio of net interest-bearing debt to EBITDA of 4.1 times (3.7).

At the end of the reporting period, loans and other interest-bearing liabilities due for repayment within one year totaled SEK 307.6 million (56.2). Loans and other interest-bearing liabilities due for repayment within one year include the following:

- » Bank loans SEK 282.1 million (-)
- » Lease liabilities of SEK 25.5 million (24.6)

At the end of the reporting period, loans and other interest-bearing liabilities due for repayment after one year or more totaled SEK 937.2 million (1,674.4). Loans and other interest-bearing liabilities due for repayment after one year or more include the following:

- » Bank loans SEK 101.4 million (-)
- » The Group's bond loan 2025/2028 of SEK 785.1 million (-), which is due for repayment in November 2028
- » Lease liabilities of SEK 50.7 million (58.7)

Loans with covenants

The Group's bond loan 2025/2028 (ISIN SE0025011885) issued on May 28, 2025 and bank facilities agreement have covenants.

At the end of the reporting period, the outstanding amount for bond loan 2025/2028 was SEK 800.0 million in nominal value. The bond loan is classified as non-current.

At the end of the reporting period, the utilised amount of credit facilities and loans under the bank facilities agreement totaled SEK 386.2 million in nominal value, of which SEK 104.1 million is classified as non-current and SEK 282.1 million is classified as current.

For information on covenants and terms and conditions, please refer to Note 8 *Liabilities with covenants*. The terms and conditions of the bond are published in their entirety on www.addvisegroup.com. At the end of the reporting period, the Group was in compliance with all covenants.

Liabilities for completed acquisitions

Liabilities for completed acquisitions amounted to SEK 44.8 million at the end of the reporting period, of which all was due for payment within one year. The liabilities consisted of contingent purchase considerations valued at fair value. Please refer to Note 6 *Calculation of fair value* for changes in contingent purchase considerations during the reporting period.

Cash flow

Operating cash flow for the quarter was SEK 41.2 million (36.6), with a change in working capital of SEK 11.5 million (0.5). Cash flow for the quarter totaled SEK -105.4 million (47.4).

Cash flow during the reporting period was affected by acquisition-related payments totaling SEK 163.1 million, presented in the condensed consolidated statement of cash flows in Investing activities. Payments of contingent purchase considerations amounted to SEK 120.7 million during the reporting period. Please also refer to Note 4 *Business combinations*.

Parent company

Net revenue at the parent company for the quarter totaled SEK 7.2 million (7.1). Operating profit was SEK -3.4 million (18.3). Loss for the period was SEK -19.5 million (1.1). Total assets amounted to SEK 1,655.5 million (2,318.1), of which equity constituted SEK 800.3 million (429.4).

Significant events during the reporting period

Public takeover offer from Amplex

On December 10, 2025, Amplex AB announced a public offer to the shareholders and warrant holders of ADDvise Group AB (publ) to transfer all shares and warrants in ADDvise to Amplex AB. On January 27, 2026, Amplex AB

announced that the offer had been accepted to such an extent that Amplex AB would become the owner of 94.31 per cent of all shares in ADDvise upon settlement of the consideration in the offer. As of February 19, 2026, Amplex AB held 99.35 per cent of the share capital and 99.01 per cent of the voting rights in ADDvise Group AB (publ).

Written procedure bonds 2025/2028

On January 2, 2026, ADDvise instructed the agent for the company's outstanding bonds 2025/2028 with ISIN SE0025011885 to initiate a written procedure in which the company requested bondholders' approval of certain amendments to the terms of the bonds.

On January 13, 2026, the agent for the bonds had received votes in favour of the proposed amendments to the bond terms from bondholders representing more than two-thirds of the total adjusted nominal amount of the bonds. Consequently, the bond agent concluded the written procedure. The amended bond terms entered into force on January 13, 2026.

Background to the written procedure

The proposed amendments in the written procedure meant that bondholders' right to request that their bonds be repurchased by the company at a price equal to 101 per cent of the nominal amount plus accrued but unpaid interest would not be triggered by (i) a change of control in relation to Amplex AB or Kenneth Lindqvist or (ii) a delisting of the company's shares from Nasdaq First North Premier Growth Market. It was against this background that ADDvise decided to initiate the written procedure.

Early voting fee and consent fee

In accordance with the terms of the written procedure, an early voting fee totaling SEK 1.9 million was paid to bondholders who fulfilled the conditions for receiving the early voting fee. In addition, a consent fee of SEK 2 million was paid to the bondholders. The consent fee was paid on a pro rata basis to all parties registered as bondholders on the record date for the payment, February 3, 2026. Nordea Bank Abp acted as consent solicitation agent, and Gernandt & Danielsson Advokatbyrå KB acted as legal advisor in the written procedure.

Statement from the independent bid committee

On January 5, 2026, the independent bid committee published a statement regarding the public takeover offer from Amplex AB. The statement regarding the offer was issued in accordance with section II.19 of the Takeover rules for certain trading platforms issued by the Stock Market Self-Regulation Committee. The

independent bid committee consisted of board members Anna Ljung and Johanne Brændgaard. According to an independent valuation opinion from Pareto, the offer was not considered fair from a financial perspective.

The independent bid committee recommended that holders of shares and warrants with a short-term perspective on their ownership or who did not wish to be owners in a listed ADDvise with a more concentrated ownership structure to accept the offer. However, the independent bid committee was of the opinion that ADDvise has the potential to create value that is greater than the offer for holders of shares and warrants who have a long-term perspective on their ownership. The press release containing the full statement was published on www.addvisegroup.com.

Compulsory redemption procedure and delisting of shares and warrants in ADDvise from Nasdaq First North

On January 29, 2026, ADDvise announced that its Board of Directors had applied for delisting of the shares and warrants in ADDvise from Nasdaq First North Premier Growth Market in accordance with the request from Amplex AB, which in connection with its public offer had become the owner of more than 90 per cent of all shares in ADDvise. Nasdaq approved the delisting application. The last day of trading in the shares and warrants in ADDvise on Nasdaq First North was February 17, 2026. Amplex AB initiated a compulsory redemption procedure regarding the shares and warrants in ADDvise that Amplex AB did not already own. At the time of publication of this interim report, the compulsory redemption procedure was ongoing.

Notice of extraordinary general meeting in ADDvise

On January 29, 2026, ADDvise convened an extraordinary general meeting at the request of Amplex AB. The meeting was held on February 16, 2026, and resolved on the Board of Directors. The Board comprises Fredrik Celsing (Chairman), Mia Tomczak and Richard Jernberg for the period until the end of the next Annual General Meeting.

Significant events after the reporting period

No significant events have occurred after the end of the reporting period.

Condensed consolidated statement of comprehensive income

SEK million	Note	Jan-Mar 2026	Jan-Mar 2025	Jan-Dec 2025	Jan-Dec 2024
Net revenue	3, 5	357.4	424.0	1,605.7	1,670.7
Capitalised work on own account		0.2	0.5	3.0	9.6
Other operating income	6	5.8	24.1	34.0	75.8
		363.4	448.6	1,642.7	1,756.1
Cost of materials		-163.3	-194.2	-738.3	-773.6
Other external expenses	4	-58.3	-55.1	-222.5	-256.4
Personnel costs		-81.2	-89.1	-322.0	-333.3
Depreciation and amortisation		-20.5	-44.1	-107.4	-86.1
Other operating expenses	6	-1.2	3.2	-20.4	-13.9
		-324.5	-379.3	-1,410.6	-1,463.3
Operating profit/loss (EBIT)		39.0	69.3	232.0	292.9
Net financial items	4, 6	-19.3	-31.7	-187.9	-148.2
<i>of which is fair value valuation of derivative financial instruments (warrants)</i>	6	-3.5	-	1.7	-
Profit/loss before tax (EBT)		19.7	37.6	44.2	144.7
Tax		-11.2	-12.0	-41.0	-54.6
Profit/loss for the period		8.4	25.6	3.1	90.0
Profit/loss attributable to:					
Shareholders of the parent company		8.4	25.6	3.1	90.0
Non-controlling interests		-	-	-	-
		8.4	25.6	3.1	90.0
Other comprehensive income					
Foreign exchange differences on the translation of foreign operations for the period		44.2	-104.9	-173.0	35.9
Change in value of financial assets measured at fair value through other comprehensive income for the period		-	-0.1	-0.1	0.1
Comprehensive income for the period		52.6	-79.4	-170.0	126.1
Comprehensive income attributable to:					
Shareholders of the parent company		52.6	-79.4	-170.0	126.1
Non-controlling interests		-	-	-	-
		52.6	-79.4	-170.0	126.1
Basic earnings per share, SEK		0.01	0.10	0.01	0.35
Diluted earnings per share, SEK		0.01	0.10	0.00	0.35

Condensed consolidated statement of financial position

SEK million	Note	Mar 31, 2026	Mar 31, 2025	Dec 31, 2025	Dec 31, 2024
ASSETS					
<i>Non-current assets</i>					
Goodwill		1,441.8	1,465.5	1,392.6	1,579.8
Trademarks		451.7	465.9	434.6	500.4
Other intangible non-current assets		195.5	221.3	200.7	241.5
Property, plant and equipment		183.8	194.4	174.7	207.2
Non-current financial assets		3.6	3.6	17.6	4.0
Contract assets		19.4	18.8	18.0	20.5
Deferred tax assets		0.0	0.0	0.0	0.0
<i>Total non-current assets</i>		<i>2,295.8</i>	<i>2,369.6</i>	<i>2,238.2</i>	<i>2,553.3</i>
<i>Current assets</i>					
Inventories		127.6	119.1	112.6	131.4
Contract assets		73.9	73.6	80.9	78.5
Trade receivables		251.5	257.5	272.4	284.2
Other current receivables		47.9	37.8	42.0	43.5
Short-term investments	6	-	-	-	123.2
Cash and bank		70.0	276.6	172.3	232.5
<i>Total current assets</i>		<i>570.8</i>	<i>764.5</i>	<i>680.3</i>	<i>893.4</i>
TOTAL ASSETS		2,866.6	3,134.1	2,918.5	3,446.7
EQUITY AND LIABILITIES					
<i>Equity</i>	9	<i>1,116.6</i>	<i>755.6</i>	<i>1,064.1</i>	<i>835.0</i>
<i>Equity attributable to:</i>					
Shareholders of the parent company		1,116.6	755.6	1,064.1	835.0
Non-controlling interests		-	-	-	-
		1,116.6	755.6	1,064.1	835.0
<i>Non-current liabilities</i>					
Interest-bearing liabilities	8	937.2	1,674.4	944.0	1,735.7
Deferred tax liabilities		151.8	160.0	147.4	169.8
Other non-current liabilities	6	9.2	31.6	10.3	95.3
<i>Total non-current liabilities</i>		<i>1,098.2</i>	<i>1,866.1</i>	<i>1,101.7</i>	<i>2,000.8</i>
<i>Current liabilities</i>					
Interest-bearing liabilities	8	307.6	56.2	261.9	54.7
Current tax liabilities		24.4	19.1	18.9	20.5
Contract liabilities		47.8	30.5	26.6	37.6
Trade payables		102.4	101.1	115.9	119.6
Derivative financial instruments	6	51.7	-	48.2	-
Other current liabilities	6	117.8	305.6	281.1	378.6
<i>Total current liabilities</i>		<i>651.7</i>	<i>512.5</i>	<i>752.7</i>	<i>610.9</i>
TOTAL EQUITY AND LIABILITIES		2,866.6	3,134.1	2,918.5	3,446.7

Condensed consolidated statement of changes in equity

SEK million	Note	Jan-Mar 2026	Jan-Mar 2025	Jan-Dec 2025	Jan-Dec 2024
Opening equity		1,064.1	835.0	835.0	613.2
Profit/loss for the period		8.4	25.6	3.1	90.0
Other comprehensive income for the period		44.2	-105.0	-173.1	36.0
Comprehensive income for the period		52.6	-79.4	-170.0	126.1
New share issue ¹	9	-0.1	-	399.1	95.7
Dividends		-	-	-	-
Change in non-controlling interests		-	-	-	-
Closing equity		1,116.6	755.6	1,064.1	835.0
Attributable to:					
Shareholders of the parent company		1,116.6	755.6	1,064.1	835.0
Non-controlling interests		-	-	-	-
Total equity		1,116.6	755.6	1,064.1	835.0

Note 1: In connection with the rights issue in April 2025, the Group issued warrants with a variable subscription price. As a result, part of the cash received from the issue is recognised as a liability.

Condensed consolidated statement of cash flows

SEK million	Note	Jan-Mar 2026	Jan-Mar 2025	Jan-Dec 2025	Jan-Dec 2024
Operating activities					
Profit/loss before tax		19.7	37.6	44.2	144.7
<i>of which interest received</i>		0.5	3.1	7.6	14.7
<i>of which interest paid</i>		-16.2	-39.9	-121.2	-165.9
Adjustments for non-cash items		19.4	7.6	166.0	28.8
Income tax paid		-9.4	-9.2	-48.2	-64.5
Cash flow before changes in working capital		29.7	36.0	162.0	109.0
Changes in working capital		11.5	0.5	-21.5	-47.3
Operating cash flow		41.2	36.6	140.5	61.7
Investing activities					
Acquisition of subsidiaries	4	-163.1	-89.9	-150.2	-189.7
Net acquisition and sale of intangible non-current assets and property, plant, and equipment		-6.7	-9.4	-34.3	-48.3
Changes in non-current financial assets		-0.8	123.1	122.6	-532.0
Investing cash flow		-170.6	23.8	-62.0	-770.1
Financing activities					
Net new share issue	9	-0.1	-	449.0	95.7
Loans, interest-bearing liabilities and non-interest-bearing liabilities raised net with amortisations	4	30.7	-5.8	-548.7	490.5
Payments made in relation to amortisation of loans attributable to leases		-6.8	-7.2	-28.7	-29.7
Deposits		0.0	0.0	0.0	-
Dividend to shareholders		-	-	-	-
Financing cash flow		23.9	-13.0	-128.3	556.6
Cash flow for the period		-105.4	47.4	-49.9	-151.8
Cash and bank at start of period		172.3	232.5	232.5	386.5
Foreign exchange differences in cash and bank		3.1	-3.4	-10.3	-2.1
Cash and bank at end of period		70.0	276.6	172.3	232.5

Consolidated income statement for five quarters

SEK million	Jan-Mar 2026	Oct-Dec 2025	Jul-Sep 2025	Apr-Jun 2025	Jan-Mar 2025
Net revenue	357.4	422.4	363.2	396.1	424.0
Capitalised work on own account	0.2	1.1	0.6	0.8	0.5
Other operating income	5.8	8.1	0.5	1.3	24.1
	363.4	431.7	364.2	398.1	448.6
Cost of materials	-163.3	-194.2	-164.1	-185.7	-194.2
Other external expenses	-58.3	-55.1	-54.2	-58.0	-55.1
Personnel costs	-81.2	-78.3	-74.7	-79.9	-89.1
Depreciation and amortisation	-20.5	-22.2	-21.0	-20.1	-44.1
Other operating expenses	-1.2	-14.1	-5.4	-4.1	3.2
	-324.5	-364.0	-319.5	-347.9	-379.3
Operating profit/loss (EBIT)	39.0	67.8	44.8	50.2	69.3
Operating margin, %	10.9%	16.0%	12.3%	12.7%	16.3%
Net financial items	-19.3	-51.7	21.0	-125.5	-31.7
<i>of which is fair value valuation of derivative financial instruments (warrants)</i>	-3.5	-32.6	44.7	-9.8	-
Profit/loss before tax (EBT)	19.7	16.0	65.8	-75.3	37.6
Tax	-11.2	-11.7	-9.8	-7.5	-12.0
Profit/loss for the period	8.4	4.3	56.0	-82.8	25.6
Profit/loss attributable to:					
Shareholders of the parent company	8.4	4.3	56.0	-82.8	25.6
Non-controlling interests	-	-	-	-	-
	8.4	4.3	56.0	-82.8	25.6
EBITA	45.5	80.2	56.4	61.3	75.3
<i>of which is business unit Healthcare</i>	30.9	45.7	37.7	35.3	49.0
<i>of which is business unit Lab</i>	19.9	41.6	22.2	33.1	34.4
EBITA margin, %	12.7%	19.0%	15.5%	15.5%	17.8%
<i>of which is business unit Healthcare</i>	13.7%	18.5%	16.1%	15.0%	18.1%
<i>of which is business unit Lab</i>	15.2%	23.5%	17.2%	20.5%	22.4%

Key performance indicators

SEK million	Jan-Mar 2026	Jan-Mar 2025	Jan-Dec 2025	Jan-Dec 2024
Net revenue	357.4	424.0	1,605.7	1,670.7
Orders received	412.8	402.5	1,574.0	1,866.1
Gross margin, %	54.3%	54.2%	54.0%	53.7%
EBITDA	59.4	113.4	339.4	379.0
EBITDA margin, %	16.6%	26.8%	21.1%	22.7%
EBITA	45.5	75.3	273.3	270.9
EBITA margin, %	12.7%	17.8%	17.0%	16.2%
Operating profit/loss (EBIT)	39.0	69.3	232.0	292.9
Operating margin, %	10.9%	16.3%	14.5%	17.5%
Profit/loss before tax (EBT)	19.7	37.6	44.2	144.7
Profit/loss for the period	8.4	25.6	3.1	90.0
Profit margin, %	2.4%	6.0%	0.2%	5.4%
Adjusted profit/loss for the period	14.1	25.7	99.0	47.1
Equity ratio, %	39.0%	24.1%	36.5%	24.2%
Net debt	-1,174.8	-1,454.0	-1,033.7	-1,434.6
Net debt to EBITDA	4.1	3.7	3.0	3.8
Number of employees at end of period	636	632	598	641
Equity per share in SEK	1.84	3.80	1.76	4.20
Return on equity, %	-1.3%	9.1%	0.3%	11.0%
Return on capital employed, %	11.1%	12.1%	12.6%	12.3%
Basic earnings per share in SEK ¹	0.01	0.10	0.01	0.35
Diluted earnings per share in SEK ¹	0.01	0.10	0.00	0.35
Number of shares at end of period	606,067,806	198,834,197	606,067,806	198,834,197
Average number of shares before dilution	606,067,806	198,834,197	498,959,788	196,710,017
Average number of shares after dilution	635,986,205	198,834,197	511,485,625	196,710,017

Please refer to Note 10 *Definition of key performance indicators* on page 14.

Note 1: Basic earnings per share and diluted earnings per share have been adjusted for the effects of the rights issue and the directed set-off issue completed in April 2025.

Condensed parent company income statement

SEK million	Jan-Mar 2026	Jan-Mar 2025	Jan-Dec 2025	Jan-Dec 2024
Net revenue	7.2	7.1	33.0	25.1
Other operating income	4.8	21.8	25.7	49.2
	12.0	28.9	58.8	74.3
Other external expenses	-8.4	-3.5	-14.4	-19.6
Personnel costs	-6.9	-10.2	-33.0	-33.1
Depreciation and amortisation	-0.1	-0.1	-0.3	-0.3
Other operating expenses	-0.0	3.2	-	-1.0
	-15.4	-10.6	-47.6	-54.0
Operating profit/loss (EBIT)	-3.4	18.3	11.1	20.3
Net financial items	-16.2	-17.2	-59.5	-27.9
Profit/loss after financial items (EBT)	-19.5	1.1	-48.4	-7.5
Appropriations	-	-	43.0	28.3
Tax	-	-	-2.2	-5.0
Profit/loss for the period	-19.5	1.1	-7.5	15.8
Parent company statement of comprehensive income				
Profit/loss for the period	-19.5	1.1	-7.5	15.8
Other comprehensive income for the period	-	-	-	-
Comprehensive income for the period	-19.5	1.1	-7.5	15.8

Condensed parent company balance sheet

SEK million	Mar 31, 2026	Mar 31, 2025	Dec 31, 2025	Dec 31, 2024
ASSETS				
<i>Non-current assets</i>				
Intangible non-current assets	0.1	0.1	0.1	0.2
Property, plant and equipment	0.4	0.5	0.4	0.6
Non-current financial assets	1,628.8	978.3	1,628.8	978.3
Receivables from group companies	-	551.7	-	604.9
Deferred tax assets	-	2.0	-	2.0
<i>Total non-current assets</i>	<i>1,629.2</i>	<i>1,532.7</i>	<i>1,629.3</i>	<i>1,585.9</i>
<i>Current assets</i>				
Receivables from group companies	18.8	569.2	56.5	566.1
Other current receivables	3.5	5.5	5.7	6.1
Short-term investments	-	-	-	123.2
Cash and bank balances	4.0	210.7	51.6	112.3
<i>Total current assets</i>	<i>26.3</i>	<i>785.4</i>	<i>113.8</i>	<i>807.7</i>
TOTAL ASSETS	1,655.5	2,318.1	1,743.1	2,393.6
EQUITY AND LIABILITIES				
<i>Equity</i>				
	800.3	429.4	819.9	428.3
<i>Non-current liabilities</i>				
Interest-bearing liabilities	785.1	1,615.7	789.1	1,668.4
Other non-current liabilities	-	-	-	-
<i>Total non-current liabilities</i>	<i>785.1</i>	<i>1,615.7</i>	<i>789.1</i>	<i>1,668.4</i>
<i>Current liabilities</i>				
Interest-bearing liabilities	-	-	-	-
Current tax liabilities	-	-	0.2	-
Trade payables	3.0	1.5	2.3	5.0
Liabilities to group companies	3.8	213.0	36.1	202.1
Derivative financial instruments	51.7	-	48.2	-
Other current liabilities	11.6	58.5	47.3	89.8
<i>Total current liabilities</i>	<i>70.1</i>	<i>273.0</i>	<i>134.1</i>	<i>296.9</i>
TOTAL EQUITY AND LIABILITIES	1,655.5	2,318.1	1,743.1	2,393.6

Notes

Note 1 Accounting policies

The report was prepared in accordance with IAS 34 Interim financial reporting and the relevant sections of the Swedish Annual Accounts Act. The accounting policies and bases of calculation applied are the same as in the most recent annual report.

The parent company's report was prepared in accordance with Chapter 9 of the Swedish Annual Accounts Act. The accounting policies and bases of calculation applied are the same as in the most recent annual report.

All amounts are stated in million Swedish kronor, MSEK, unless otherwise indicated.

Note 2 Related party transactions

During the reporting period, there has been no transactions with related parties other than those decided by the general meeting. As of March 31, 2026 ADDvise Group was a subsidiary of Amplex AB, which has significant influence over ADDvise through its ownership and representation on the Board of Directors.

Note 3 Segment reporting

ADDvise's segment information is presented from the company management's perspective, with operating segments identified based on internal reporting to the company's ultimate operating decision maker. The CEO is ADDvise's ultimate operating decision maker.

ADDvise's operating segments comprise two business units: Lab and Healthcare. The Lab business unit provides laboratory furnishings, safety ventilation, climate rooms, clean rooms, and laboratory apparatus to the pharmaceutical and life science research industries. The Healthcare business unit manufactures and distributes medical equipment, as well as pharmaceuticals and consumables for healthcare units. This classification reflects the company's internal organisation and reporting system. Internal pricing is on market terms. Intra-Group profits are eliminated.

Unallocated Group expenses include, for example, costs for parent company functions. These costs are offset against the service fees received by the parent company.

SEK million	Jan-Mar 2026	Jan-Mar 2025	Jan-Dec 2025	Jan-Dec 2024
Lab business unit	130.8	153.5	620.7	645.8
Healthcare business unit	226.6	270.5	985.0	1,024.9
Total external net revenue	357.4	424.0	1,605.7	1,670.7
Lab business unit	0.0	0.0	0.1	0.1
Healthcare business unit	-	-	0.5	0.3
Total internal net revenue	0.0	0.0	0.6	0.4
Lab business unit	-65.1	-70.4	-298.8	-314.9
Healthcare business unit	-98.2	-123.9	-439.5	-458.7
Total cost of materials	-163.3	-194.2	-738.3	-773.6
Lab business unit	19.9	34.4	131.4	140.0
Healthcare business unit	30.9	49.0	167.7	154.6
Total EBITA for the operating segments	50.8	83.4	299.0	294.6
Unallocated Group expenses	-5.3	-8.1	-25.8	-23.7
Consolidated EBITA	45.5	75.3	273.3	270.9
Amortisation and impairment of intangible assets attributable to acquisitions	-5.6	-28.4	-45.5	-23.9
Acquisition costs	-0.2	-0.4	-1.9	-8.9
Revaluation of estimated additional purchase consideration for completed acquisitions	4.9	25.7	12.2	61.4
Non-recurring costs	-5.6	-2.9	-6.0	-6.6
Consolidated operating profit/loss (EBIT)	39.0	69.3	232.0	292.9
Net financial items	-19.3	-31.7	-187.9	-148.2
Consolidated profit/loss before tax (EBT)	19.7	37.6	44.2	144.7

Note 4 Business combinations

No acquisitions were completed during the reporting period.

Transaction costs

During the reporting period, transaction costs of SEK 1.0 million are recognised as costs in the consolidated statement of comprehensive income, of which SEK 0.2 million is reported in *Other external expenses* and SEK 0.8 million is reported in *Net financial items*.

Net outflow of cash – investing activities

Cash outflow for the acquisition of subsidiaries, after deduction of cash and cash equivalents acquired:

SEK million	Jan-Mar 2026	Jan-Mar 2025	Jan-Dec 2025	Jan-Dec 2024
Cash purchase consideration	120.7	89.9	150.2	158.8
Holdback amounts and promissory notes (investing activities)	42.4	-	-	-
Holdback amounts and promissory notes (financing activities)	-	5.7	5.7	123.3
Cash and cash equivalents acquired	-	-	-	-1.0
Decrease in cash and cash equivalents acquired	-	-	-	31.9
Net outflow of cash	163.1	95.6	156.0	313.1
<i>Of which is net outflow of cash in investing activities</i>	<i>163.1</i>	<i>89.9</i>	<i>150.2</i>	<i>189.7</i>

Cash outflow for January–March 2026 comprises payments of purchase considerations to the former owners of subsidiaries acquired before 2026.

Note 5 Allocation of income

In accordance with IFRS 15 Revenue from Contracts with Customers, income is recognised and allocated to primary geographic markets, based on customer domicile.

SEK million	Jan-Mar 2026			Jan-Mar 2025		
	Lab	Health-care	Total	Lab	Health-care	Total
Europe	84.7	36.2	120.9	92.1	49.8	142.0
North America	37.1	134.6	171.8	35.3	166.5	201.8
South America	1.9	53.4	55.3	-	48.2	48.2
Rest of the world	7.1	2.4	9.5	26.1	6.0	32.1
Total	130.8	226.6	357.4	153.5	270.5	424.0

During the third quarter of 2025, the distribution of net revenue by primary geographic markets was updated for previous periods in 2025 in the Healthcare business unit. Total net revenue and the distribution between segments were unchanged.

SEK million	Jan-Dec 2025			Jan-Dec 2024		
	Lab	Health-care	Total	Lab	Health-care	Total
Europe	401.6	188.4	590.0	382.3	174.4	556.7
North America	150.9	576.0	726.9	119.6	623.8	743.5
South America	0.0	202.4	202.4	-	220.1	220.1
Rest of the world	68.3	18.2	86.4	143.9	6.6	150.4
Total	620.7	985.0	1,605.7	645.8	1,024.9	1,670.7

Note 6 Calculation of fair value

The table below lists financial instruments measured at fair value, based on the classification in the fair value hierarchy. The different levels are defined as follows:

- » Level 1 – Quoted prices (unadjusted) in active markets
- » Level 2 – Inputs other than quoted market prices included within Level 1 that are observable for the asset or liability, either directly or indirectly
- » Level 3 – Unobservable inputs for the asset or liability

SEK million	March 31, 2026		
	Level 1	Level 2	Level 3
Financial liabilities			
Warrants	-	51.7	-
Contingent purchase consideration	-	-	44.8
Total financial liabilities	-	51.7	44.8

At the end of the reporting period, the warrants were no longer listed. The fair value of the warrants as of March 31, 2026 was based on the price of the warrants according to the public offer from Amplex AB.

continuation of Note 6; see next page

SEK million	March 31, 2025		
	Level 1	Level 2	Level 3
Financial liabilities			
Contingent purchase consideration	-	-	225.2
Total financial liabilities	-	-	225.2

SEK million	December 31, 2025		
	Level 1	Level 2	Level 3
Financial liabilities			
Warrants	48.2	-	-
Contingent purchase consideration	-	-	167.4
Total financial liabilities	48.2	-	167.4

SEK million	December 31, 2024		
	Level 1	Level 2	Level 3
Financial assets			
Short-term investments	123.2	-	-
Total financial assets	123.2	-	-
Financial liabilities			
Contingent purchase consideration	-	-	348.3
Total financial liabilities	-	-	348.3

Fair value description

Short-term investments

Short-term investments, which comprised bonds during the comparison periods, are traded on an active market, with the fair value calculated on the basis of the last buy price quoted on the balance sheet date.

Warrants

Warrants refer to warrants issued by the Group with a subscription price range. The fair value of the warrants at the end of the comparison periods was based on the quoted price as of the closing date. The fair value of the warrants at the end of the reporting period was based on the price in the public offer from Amplex AB.

Contingent purchase consideration

Contingent purchase consideration refers to the estimated contingent additional purchase consideration for completed acquisitions. At the end of the reporting period, the majority of contingent purchase considerations were based on key performance indicators that must be met in the acquired subsidiaries. One acquisition has contingent purchase considerations based on a key performance indicator and also contingent purchase considerations based on a non-financial condition.

Contingent purchase considerations for acquisitions completed at the end of the reporting period, are estimated to amount to SEK 44.8 million. If the subsidiaries do not reach the required targets, no contingent purchase consideration is paid. An estimate of the range for possible outcomes of contingent purchase consideration is from SEK 22.0 million to SEK 69.0 million at the end of the reporting period.

The fair value of contingent purchase considerations is subject to currency risk. At the end of the reporting period, the fair value of contingent purchase considerations can be affected by changes in SEK versus BRL and USD. A change in the currency exchange rate for BRL of 5% would have an effect of SEK 1.1 million on the valuation of contingent purchase considerations and SEK 0.0 million on profit/loss before tax. A change in the currency exchange rate for USD of 5% would have an effect of SEK 1.1 million on the valuation of contingent purchase considerations and SEK 0.0 million on profit/loss before tax.

Reconciliation of level 3

The change in financial instruments in level 3, Contingent purchase consideration, is presented below:

SEK million	Jan-Mar 2026	Jan-Dec 2025	Jan-Dec 2024
Fair value at the beginning of the year	167.4	348.3	443.4
Change	-117.7	-168.6	-32.8
<i>Of which is attributable to contingent purchase considerations paid</i>	-120.7	-148.3	-28.1
<i>Of which is attributable to contingent purchase considerations for this year's acquisitions</i>	-	-	-
<i>Of which is attributable to exchange rate differences</i>	3.0	-20.3	-4.7
Changes affecting profit/loss	-4.9	-12.2	-62.3
<i>Of which is posted on the line Other operating income</i>	-4.9	-29.1	-73.4
<i>Of which is posted on the line Other operating expenses</i>	-	16.8	11.1
Fair value at the end of the year/period	44.8	167.4	348.3

Changes affecting profit/loss on the line *Other operating income* include write-downs of contingent purchase considerations in an amount of SEK 4.5 million and currency exchange gains in an amount of SEK 0.4 million.

Note 7 Financial risks

ADDvise is exposed to a number of different financial risks through its activities, such as market risk, credit risk, currency risk and liquidity risk. The Group management and the Board of Directors take active steps to minimise these risks.

The Group's operations involve a liquidity risk, since large orders tie up significant capital. To minimise the amount of capital tied up, the Group has payment terms with the Group's customers that require a portion of the order value to be paid in advance on the signing of the order.

Since the Group's strategy is to make complementary acquisitions, the Group's level of debt may change over time. The Board of Directors always makes an overall assessment of the risk that any acquisition financing represents to the Group.

Note 8 Liabilities with covenants

The Group's senior unsecured bond loan 2025/2028 with an issue date of May 28, 2025 and secured bank facilities agreement have covenants. The Group was in compliance with the covenants at the end of the reporting period. The bond loan is classified as non-current. The part of the utilised bank facilities due after one year or more is classified as non-current, and the part due within one year is classified as current.

The covenant for the bond loan is linked to the ratio of net debt to EBITDA and is evaluated prior to increased indebtedness or dividends to shareholders ("incurrence test"). Bond loan 2025/2028 is due on November 28, 2028, and amounted to SEK 800.0 million in nominal value at the end of the reporting period. The complete terms and conditions of the bond loan are published on www.addvisegroup.com.

The covenant for the facilities agreement is linked to the ratio between utilised facilities within the framework of the facility agreement, so-called "Super Senior Debt", and EBITDA. The covenant is evaluated quarterly as of the end of the periods covered by the Group's interim reports, that is March 31, June 30, September 30 and December 31, and prior to increased indebtedness or dividends to shareholders. Utilisation of the bank facilities amounted to SEK 386.2 million at the end of the reporting period.

Facilities agreement covenant

The table presents the calculation of the covenant according to the facilities agreement. The first evaluation of the covenant was as of June 30, 2025, in line with the agreement. No comparison numbers have been calculated for periods prior to signing of the facilities agreement.

SEK million	Mar 31, 2026	Dec 31, 2025
Utilisation of facilities agreement, "Super Senior Debt"	386.2	342.1
EBITDA rolling 12-month period	285.5	339.4
Reversal of non-recurring costs, acquisition costs and revaluations of estimated earn-outs for completed acquisitions rolling 12-month period	19.0	-4.3
Pro forma EBITDA from new acquisitions	-	-
= EBITDA rolling 12-month period according to facilities agreement	304.5	335.1
= "Super Senior Debt" to EBITDA according to facilities agreement	1.27	1.02
Covenant for facilities agreement	1.50	1.50

Note 9 Equity

At the beginning of the financial year 2026, the number of shares in ADDvise amounted to 606,067,806, of which 22,858,315 were class A shares and 583,209,491 were class B shares. The share capital amounted to SEK 60,606,780.60.

At the end of the reporting period, the number of shares in ADDvise amounted to 606,067,806, of which 22,858,315 were class A shares and 583,209,491 were class B shares. The share capital amounted to SEK 60,606,780.60.

No of shares

	Jan-Mar 2026	Jan-Mar 2025	Jan-Dec 2025	Jan-Dec 2024
Average number of shares before dilution	606,067,806	198,834,197	498,959,788	196,710,017
<i>Adjustments to calculate earnings per share after dilution:</i>				
Warrants series TOIA (class A shares)	1,147,817	-	1,602,002	-
Warrants series TOIB (class B shares)	28,770,582	-	10,923,835	-
Average number of shares after dilution	635,986,205	198,834,197	511,485,625	196,710,017

At the time of issuance of the January–March 2026 interim report, the final outcome of the warrants had not yet been determined. The exercise period for the company's outstanding warrants of series TOIA and TOIB coincided with the ongoing compulsory redemption procedure initiated by Amplex AB.

Note 10 Definition of key performance indicators

In its financial reports, ADDvise uses alternative performance measures, in other words financial measures that are not defined by IFRS. Management uses these performance measures to assess the Group's financial development as a complement to the performance indicators that represent generally accepted accounting practice. Described below are financial measures not defined by IFRS. Unless otherwise stated in the respective key performance indicator definition, the Group's definition of the key performance indicator is unchanged from previous periods.

Financial measures that use items not otherwise presented in financial statements or by other facts in this interim report are described with detailed calculations.

Adjusted profit/loss for the period

Adjusted profit/loss for the period is a key performance indicator that the Group considers relevant for an investor who wants to see profit/loss for the period excluding items attributable to acquisitions and non-recurring costs.

SEK million	Jan-Mar 2026	Jan-Mar 2025	Jan-Dec 2025	Jan-Dec 2024
Profit/loss for the period	8.4	25.6	3.1	90.0
Reversal of acquisition costs	0.2	0.4	1.9	8.9
Reversal of revaluations of estimated contingent purchase considerations for completed acquisitions	-4.9	-25.7	-12.2	-61.4
Reversal of non-recurring costs	5.6	2.9	6.0	6.6
Reversal of non-recurring financial items	4.7	-	78.0	2.9
Reversal of impairment of intangible assets attributable to acquisitions	-	22.5	22.1	-
= Adjusted profit/loss for the period	14.1	25.7	99.0	47.1

Average number of shares after dilution

Weighted average of the number of shares outstanding during the period in the event that issued warrants are exercised. This performance indicator is as defined by IFRS, but is described here for information purposes.

Average number of shares before dilution

Weighted average of the number of shares outstanding during the period without taking into account issued warrants. This performance indicator is as defined by IFRS, but is described here for information purposes.

Basic earnings per share

Profit/loss for the period attributable to the parent company's shareholders as a proportion of the average number of shares before dilution, with earnings per share adjusted to take into account new share issues at a discount (the subscription price is lower than the current closing price). This performance indicator is as defined by IFRS, but is described here for information purposes.

Capital employed

The Group defines capital employed as equity plus non-current interest-bearing liabilities plus current interest-bearing liabilities minus cash and cash equivalents minus short-term investments, calculated as the average of the last four quarters.

Diluted earnings per share

Profit/loss for the period attributable to the parent company's shareholders as a proportion of the average number of shares after dilution, with earnings per share adjusted to take into account new share issues at a discount (the subscription price is lower than the current closing price). This performance indicator is as defined by IFRS, but is described here for information purposes.

EBITA

EBITA is a key performance indicator that the Group considers relevant for an investor who wants to understand the profit generation of the Group. The Group defines earnings before interest, tax and amortisation (EBITA) as operating profit from continuing operations excluding amortisation and impairment of intangible assets attributable to acquisitions, adjusted for acquisition costs, revaluations of estimated contingent purchase considerations for completed acquisitions and non-recurring costs.

SEK million	Jan-Mar 2026	Jan-Mar 2025	Jan-Dec 2025	Jan-Dec 2024
Operating profit/loss, see below	39.0	69.3	232.0	292.9
Reversal of amortisation and impairment of intangible assets attributable to acquisitions	5.6	28.4	45.5	23.9
Reversal of acquisition costs	0.2	0.4	1.9	8.9
Reversal of revaluations of estimated contingent purchase considerations for completed acquisitions	-4.9	-25.7	-12.2	-61.4
Reversal of non-recurring costs	5.6	2.9	6.0	6.6
= EBITA	45.5	75.3	273.3	270.9

EBITA margin

EBITA, see above, as a percentage of net sales.

EBITDA

EBITDA is a measure that the Group considers relevant for an investor wishing to understand profit generation before investments in non-current assets. The Group defines earnings before interest, tax, depreciation and amortisation (EBITDA) as operating profit/loss from continuing operations excluding depreciation, amortisation and impairment relating to tangible and intangible assets.

EBITDA margin

Operating profit/loss before depreciation and amortisation as a percentage of net revenue.

Equity per share

Equity at the end of the period attributable to the parent company's shareholders divided by the number of shares at the end of the period.

Equity ratio

Adjusted equity as a percentage of total assets.

Gross margin

Net revenue minus cost of materials as a percentage of net revenue.

Net debt

The Group defines net debt as the net sum of cash and bank plus short-term investments and interest-bearing liabilities. The Group monitors this performance indicator since it shows the level of debt and is part of one of the long-term financial targets adopted by the Board of Directors.

Net debt to EBITDA

The Group defines net debt to EBITDA as the net sum of cash and bank plus short-term investments and interest-bearing liabilities divided by pro forma EBITDA on a rolling 12-month basis. The Group monitors this performance indicator since it shows the level of debt and is one of the financial targets adopted by the Board of Directors. For a definition of EBITDA, see above.

continuation of Note 10; see next page

Non-recurring costs

The Group defines non-recurring costs as discernable costs arising from identifiable, non-recurring events that are outside the normal course of business. These costs must be clearly documented and have a direct link to a specific event, such as a major restructuring or regulatory requirement. The costs should not be recurring or related to the day-to-day operations. In the calculation of the key performance indicators EBITA and adjusted profit/loss for the period, these costs are excluded according to the established definition. See the definitions of these key performance indicators for amounts.

Number of employees

The number of employees working at the end of the period.

Operating margin

Operating profit/loss as a percentage of net revenue.

Operating profit/loss (EBIT)

Profit/loss before financial items and tax.

OPEX

The Group defines OPEX (operating expenses) as the sum of other external expenses, personnel costs and other operating expenses. The Group monitors this performance indicator since it shows the effectiveness of cost-saving initiatives and cost control.

Orders received

New customer orders received during the period, plus additions and deductions for changes to customer orders received earlier in the current financial year. Additions and deductions are made for changes to larger customer orders with delivery schedules spread across several financial years even if the customer order was received in a previous year.

Organic growth

Net revenue and orders received in acquired companies are included in the calculation of organic growth 12 months after the acquisition date. A company that is consolidated from March of year 1 is included in the calculation of organic growth from March of year 2.

Pro forma numbers

The numbers in pro forma key performance indicators are pro forma numbers for a full year or a rolling 12-month period, and have not been reviewed by the company's auditor. The numbers are including all acquisitions from the start of the year or the rolling 12-month period until the publication of this report.

Profit/loss before tax (EBT)

Profit/loss after net financial items.

Profit margin

Profit/loss for the period as a percentage of net revenue.

Return on capital employed

The Group defines return on capital employed as EBITA rolling 12 months divided by average capital employed over 4 quarters. For the calculation of EBITA and capital employed, see above.

SEK million	Mar 31, 2026	Mar 31, 2025	Dec 31, 2025	Dec 31, 2024
EBITA rolling 12 months, see above	243.5	268.1	273.3	270.9
Divided by average capital employed 4 quarters, see above	2,184.4	2,216.3	2,163.9	2,196.6
= Return on capital employed as a %	11.1%	12.1%	12.6%	12.3%

Return on equity

The Group defines return on equity as profit/loss for the period on a rolling 12-month basis divided by average equity for 4 quarters. The key performance indicator is presented for increased transparency.

Other information

About ADDvise

ADDvise is an international life science group. Operating a decentralised ownership model, we develop and acquire high quality companies. The Group comprises more than 20 companies and generates annual revenues of close to SEK 1.6 billion. Since 2026, ADDvise is a business area within the privately owned Swedish group Amplex AB.

Long-term financial targets

ADDvise's financial targets represent an ambition to be achieved over a period of several years through a combination of organic growth and acquisitions. The focus is on balancing a high return on capital employed (ROCE) with strong EBITA growth while maintaining a healthy level of debt.

- » *Growth*: ADDvise shall have an average annual EBITA growth of 15%. Growth will be achieved organically as well as through acquisitions.
- » *Return*: ADDvise shall annually reach a return on capital employed (ROCE) of 15%.
- » *Capital structure*: ADDvise's ratio of net interest-bearing debt to EBITDA shall not exceed 3.0 times.
- » *Dividend*: ADDvise shall distribute up to 25% of previous year's profit in dividend to shareholders.

Publication dates for financial information

Annual general meeting	Jun 29, 2026
Interim report (Jan–Jun 2026)	Aug 13, 2026
Interim report (Jan–Sep 2026)	Nov 12, 2026
Year-end report 2026 (Jan–Dec)	February 11, 2027

This information is information that ADDvise Group AB is required to disclose under the EU Market Abuse Regulation. The information was submitted for publication on April 29, 2026 at 07:45 CEST. This report, as well as further information, is available on ADDvise's website, www.addvisegroup.com

For further information, please contact:

Staffan Torstensson, CEO
+46(0)70-433 20 19
staffan.torstensson@addvisegroup.se

Johan Irwe, CFO
+46(0)73-731 26 11
johan.irwe@addvisegroup.se

ADDvise Group AB (publ)
Grev Turegatan 30, SE-114 38 Stockholm
Sweden

Review of interim report

This interim report has not been reviewed by the company's auditor.

Declaration

The undersigned declare that the interim report presents fairly the business, financial position and performance of the parent company and the Group and describes the significant risks and uncertainties faced by the parent company and the constituent companies of the Group.

Stockholm, April 29, 2026

Fredrik Celsing
Chairman of the Board

Mia Tomczak
Board Member

Richard Jernberg
Board Member